With the rapid changes in lifestyle in modern society, including the high nutritional intake and reduced physical activity, the incidence of metabolic diseases has been increasing year by year. Obstructive sleep apnea syndrome (OSAS) is a sleep disorder, usually characterized by sudden pauses of breathing during sleep and an interrupted sleep rhythm. Although the pathological mechanism remains poorly understood, it has been strongly associated with metabolic diseases, including obesity, insulin resistance, type 2 diabetes mellitus (T2DM), and nonalcoholic fatty liver disease (NAFLD). In the present mini-review, we briefly summarize the connections between OSAS, obesity, T2DM, and NAFLD, which might help us to better understand the pathogenesis of human diseases. (Endocrinology 159: 2670(Endocrinology 159: -2675(Endocrinology 159: , 2018 D uring the past decade, with the rapid advances in the economy and increases in individual living standards, metabolic diseases, such as obesity, type 2 diabetes mellitus (T2DM), and nonalcoholic fatty liver disease (NAFLD), have emerged as serious threats to the health of people. The global prevalence of T2DM among adults aged .18 years has increased from 4.7% in 1980 to 8.5% in 2014 (1). Epidemiological surveys have revealed that the prevalence of T2DM has exceeded 10% in China and the United States (2, 3), and the incidence of NAFLD has exceeded 15% (4). Metabolic diseases are not merely limited to glucose and lipid metabolism disorders; they are also related to cardiovascular and cerebrovascular diseases, diabetic nephropathy, diabetic neuropathy, and tumorigenesis. In addition, with the increasing epidemic of obesity and metabolic diseases, the prevalence of obstructive sleep apnea syndrome (OSAS) among adults has also been increasing. OSAS is caused by narrowing, obstruction, and nerve regulatory factor obstacles within the upper respiratory tract. This complex syndrome manifests with sleep apnea and hypopnea and is accompanied by hypoxia, snoring, daytime sleepiness, and other symptoms (5, 6). The prevalence of OSAS is~3% to 7%, and obesity is a dominant risk factor. For adults with obesity, the prevalence of OSAS has increased to 42% to 48% for men and 8% to 38% for women (7), suggesting a sex difference. The data collected from 23,806 patients examined using -whole-night polysomnography showed that the OSAS severity varies with age in both sexes, with women experiencing a less severe syndrome in all ages (8). Moreover, patients with OSAS have a greater risk of T2DM and related metabolic disorders. In the present review, we discuss the current state of research addressing the relationship between OSAS and metabolic diseases.
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OSAS and Obesity
The accumulation of visceral fat in obese patients is a key risk factor for OSAS. The analytical results obtained from examining the intra-abdominal fat areas of obese patients with or without OSAS showed that obese patients with OSAS have a significantly larger visceral fat area and an increased ratio of visceral to total fat compared with obese patients without OSAS (9) . In addition, the apnea-hypopnea index (AHI), an index used to indicate the severity of sleep apnea and represented by the number of apnea and hypopnea events per hour of sleep, has been positively correlated with the size of the visceral fat area, indicating that the incidence of OSAS increases in patients with large visceral fat areas (10, 11) . Therefore, visceral adipose tissue is a key risk factor for OSAS.
However, the molecular mechanism by which obesity causes OSAS remains poorly understood. Some studies have demonstrated that excessive accumulation of fat in the respiratory area results in narrowing and declined diastolic function of the respiratory tract. Furthermore, the accumulation of fat in the diaphragm leads to weaker breath. It has, therefore, been postulated that the accumulation of fat at the upper portion of the body, especially around the neck, plays a substantial role in inducing OSAS. More fat tends to accumulate in these areas with an increasing severity of obesity (10, 11) . The frequency of the AHI gradually increases with increasing body weight, and the average sleep apnea time becomes significantly prolonged (10, 11) .
In addition, a myriad of studies have demonstrated that the adipose tissue is not only the place in which the body stores energy and triglycerides but is also an important endocrine organ. A number of cytokines and inflammatory factors secreted by the adipose tissue regulate the homeostasis of glucose and lipid metabolism and play key roles in the morbidity of OSAS. First, leptin, a peptide hormone encoded by the ob gene, regulates appetite, obesity, and insulin sensitivity by binding to its receptor (leptin receptor) (12) . Many reports have demonstrated that serum leptin levels are positively correlated with the AHI, hypoxemia, and body mass index in patients with OSAS (13, 14) . Thus, the higher the serum leptin level, the greater the AHI and the longer the duration of hypoxemia (13) (14) (15) (16) . In addition, De Santis et al. (17) reported that the plasma levels of leptin are markedly reduced in patients with OSAS treated with continuous positive airway pressure. Thus, it was predicted that the high concentration of leptin in serum could be involved in the pathogenesis of OSAS. Although the reasons for the higher leptin levels in OSAS remain poorly understood, we have speculated that leptin resistance, a very common condition in obese patients (18) , can directly induce hyperleptinemia. In addition, several reports have shown that chronic exposure of adipocyte to hypoxia, the primary player in OSAS, can lead to upregulation of leptin mRNA levels (19) (20) (21) . In contrast, leptin receptor gene polymorphisms have been found to be related to obesity and OSAS (22, 23) . Dubey et al. (23) observed an association of Q223R gene polymorphism with high blood pressure and nocturnal maximum pulse rate in patients with OSAS from North India. Furthermore, a polymorphism in K656N was correlated with the AHI, the average level of desaturation, and the levels of high-density lipoprotein cholesterol (23) . The role of the leptin receptor gene polymorphisms in OSAS pathogenesis remains unclear. It has been proposed that the polymorphism is located in exons, which might affect the functionality of the leptin receptor and its downstream signal transduction (22, 23) . The altered signaling might generate a leptin-resistance state, causing obesity and OSAS.
Second, decreases in adiponectin, a 244-amino acid protein present in cells and tissues with various configurations, might be related to OSAS (24) . Adiponectin activates AMP kinase and other signaling pathways through adiponectin receptors 1 and 2 and plays a critical role in maintaining insulin sensitivity and the homeostasis of glucose and lipid metabolism (25) . It has been reported that adiponectin levels are significantly reduced in obese patients compared with those of normal weight (26) . Consistently, the circulating adiponectin levels have been substantially lower in patients with OSAS and have correlated negatively with the AHI (27, 28) . This indicates that adiponectin is not only a marker that might predict the incidence of OSAS but also has a protective role. For example, OSAS is a risk factor contributing to cardiovascular morbidity and mortality, in part due to chronic intermittent hypoxia (CIH) (6) . The results from animal models showed that adiponectin treatment could significantly improve CIH-induced myocardial injury and ventricular dysfunction via inhibition of endoplasmic reticulum (ER) stress and TGF-b/smad2/3 pathway (29, 30) . Third, resistin, a secreted cysteine-rich adipokine, promotes the expression of TNF-a, IL-6, and other inflammatory cytokines by activating pathways such as nuclear factor kB (NF-kB), and leads to the development of insulin resistance (31) . It has been reported that the circulating resistin levels of obese patients with OSAS are significantly greater than those in healthy individuals. Moreover, the high concentration of resistin might be a potential risk factor for OSAS-induced arteriosclerosis (32, 33) . Fourth, visfatin, which was discovered and isolated from abdominal adipose tissue by a Japanese research group in 2005, is actively involved in physiological and pathological processes, such as insulin secretion, adipose differentiation, and inflammatory responses (34) . Additionally, plasma visfatin levels from patients with OSAS were positively correlated with sleep latency and triglyceride levels but negatively with rapid eye movement sleep and low-density cholesterol (35) . However, the visfatin plasma concentration did not directly correlate with insulin sensitivity and intermittent hypoxia (35) . Acıoglu et al. (36) revealed that patients with OSAS with enhanced plasma visfatin levels were characterized by increased neck and waist circumferences. This finding indicates that circulating visfatin concentrations could be used as a biomarker of OSAS. Fifth, inflammatory factors, including TNF-a, IL-6, IL1b, and IL-18, inhibit insulin receptors and the phosphorylation of insulin receptor substrates by activating NF-kB, c-Jun N-terminal kinase, and other downstream signaling pathways. Such factors contribute dramatically to the development of the insulin resistance associated with obesity (37, 38) . Studies have demonstrated that inflammatory cytokines are significantly increased in the plasma of patients with OSAS (39), and their levels become remarkably reduced after continuous positive airway pressure therapy (40) . Therefore, inflammatory cytokines are associated with the pathophysiological processes of OSAS. In summary, abnormally secreted adipokines and inflammatory cytokines play important roles in the pathogenesis of OSAS. Further studies into their mechanisms could provide promising strategies for treating OSAS.
OSAS and T2DM
The incidence of hyperglycemia, insulin resistance, and T2DM in patients with OSAS is much greater than the incidence in healthy people. The decline in sleep oxygen saturation levels has also been correlated with the fasting blood glucose level and the blood glucose concentration in the 2-hour oral glucose tolerance test, indicating that the severity of OSAS correlates positively with insulin resistance (41) . More importantly, the relationship between OSAS and insulin resistance also applies to nonobese patients. The data from multiple populations have shown that AHI is an independent risk factor for insulin resistance and T2DM. The strength enhancement in the level of insulin resistance is 0.5% with every 1-unit increase in AHI (7, 42) . Some studies have reported that the intermittent hypoxemia and oxidative stress in patients with OSAS could be key factors leading to insulin resistance (43) . These results have shown that hypoxemia can affect ATP synthesis in pancreatic islet b-cells and thereby inhibit insulin secretion. Second, hypoxemia decreases the phosphorylation of insulin receptor tyrosine kinases and reduces the effects and sensitivity of the insulin receptors. Third, hypoxemia promotes the excitability of sympathetic nerves, which can elevate the blood glucose level and impair glucose tolerance by improving liver glycogenolysis and gluconeogenesis processes. Fourth, hypoxemia and hypercapnia can stimulate chemoreceptors, leading to increased levels of epinephrine and glucocorticoid to antagonize the biological effects of the insulin. Finally, hypoxemia and oxidative stress cause the expression and release of inflammatory cytokines, resulting in insulin resistance. Moreover, the irregular and incomplete sleep of patients with OSAS results in drowsiness during the day, a prolonged total sleep time, decreased activity and energy expenditure, weight gain, the deposition of adipose tissue, ectopic fat deposition, and the exacerbation of obesity, further aggravating the incidence of insulin resistance and hyperglycemia and leading to T2DM.
OSAS and NAFLD
NAFLD, including simple steatosis and nonalcoholic steatohepatitis (NASH), is a metabolic disease characterized by the excessive intrahepatic deposition of triglycerides (44) . Some patients with NAFLD could develop liver fibrosis, cirrhosis, and even liver cancer (44) . Many studies have shown that patients with OSAS have a high incidence of NAFLD compared with that of the normal population (45, 46) , indicating that patients with OSAS should be screened for the presence and severity of NAFLD. Cakmak et al. (45) examined 137 patients (76 women and 61 men) and found that the AHI and oxygen desaturation index were significantly greater in the moderate and severe NAFLD group than in the non-NAFLD group. In 80 patients with biopsy-proven pediatric NAFLD (56% males), Nobili et al. (47) showed that OSAS is associated with increased endotoxemia, coupled with impaired gut barrier function, which resulted in hepatic susceptibility to endotoxemia and an expansion of an adiponectin-deficient hepatic progenitor cell pool. At the molecular level, it has been suggested that the CIH in OSAS might induce liver injury, lipid deposit, inflammation, and fibrogenesis by activating or inducing hypoxia inducible factors (HIFs), NF-kB, ER stress, adipose tissue inflammation, and insulin resistance, which all provide potential molecular mechanisms linking OSAS to NAFLD (48) . Under normoxia conditions, a portion of the amino acids in the a-protein of HIF are hydroxylated, recognized, and degraded by the ubiquitin ligase von Hippel-Lindau. However, in a hypoxic environment, those amino acids are dehydroxylated and then bind to HIF1b to form an active HIF protein, which then enters the nucleus and binds to the promoters of downstream genes to regulate gene transcription (49, 50) . Data from animal experiments have indicated that liver-specific overexpression of HIF1a or HIF2a results in the deposition of triglycerides, which enhances the incidence of NAFLD (51, 52) . In contrast, liver-specific knockdown of HIF1a or HIF2a reduce triglyceride deposition in the liver and prevent the onset of NAFLD (51, 52) . This has mainly been attributed to the target genes regulated by HIF1a and HIF2a. HIF1a primarily regulates glycolysis and pyruvate metabolism, and HIF2a predominantly controls fatty acid metabolism (51, 52) . Moreover, HIF1a and HIF2a might promote or aggravate NAFLD, NASH, and hepatic fibrosis by mediating the expression of inflammatory factors, profibrotic factors, and/or angiogenic factors in Kupffer cells and satellite cells (51) .
In addition to the HIF protein, intermittent hypoxia in OSAS can activate the ER stress pathway. When unfolded or misfolded proteins accumulate in the lumen of the ER, cells respond by activating a series of signal transduction pathways, known as the unfolded protein response (UPR). This response enhances the protein folding capacity, stops most protein translation, and accelerates protein degradation to maintain the homeostasis of the intracellular environment (53) (54) (55) . The UPR is mediated by three important sensor proteins: double-stranded RNA-dependent protein kinaselike ER kinase (PERK), inositol requiring enzyme 1, and activating transcription factor 6 (53-55). Under normal circumstances, all three proteins are bound to glucoseregulated protein 78 with no or low activity. When the ER is under stress, glucose-regulated protein 78, in turn, binds to unfolded or misfolded proteins to activate the three UPR pathways (53) (54) (55) . Numerous animal studies have shown that the UPR pathways in essential metabolic organs, such as the liver and muscle tissues, are activated in obese patients, thereby promoting the incidence and development of NAFLD and glycolipid metabolism disorders (56) . For example, a study reported by Ozcan et al. (57) showed that phosphorylation of inositol requiring enzyme 1 and PERK in the liver tissue of obese or ob/ob mice induced by a high-fat diet is significantly increased, indicating activation of ER stress and the UPR pathways. In contrast, tauroursodeoxycholic acid treatment in obese mice alleviated ER stress and reduced hepatic triglyceride deposition and abnormal glucose tolerance (58) . Moreover, studies have shown that the UPR pathways are substantially activated in the liver tissues of intermittently hypoxic mice, including increased phosphorylation of PERK (59) . Collectively, these data indicate that activation of HIFs and ER stress in chronic hypoxemic conditions might represent the mechanisms for OSAS-induced liver diseases.
Conclusion
OSAS is closely related to the presence of obesity, insulin resistance, T2DM, NAFLD, and related metabolic diseases (60) . However, the underlying mechanisms of these diseases require further exploration using animal models and clinical data. However, because of the lifestyle changes in modern society, such as the high nutritional intake and reduced physical activity, the incidence of these diseases has been increasing rapidly. Therefore, it is urgent and necessary to screen patients with OSAS for metabolic diseases and to reduce the incidence of metabolic diseases in patients with OSAS by the implementation of appropriate treatment strategies.
